{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:30:40Z","timestamp":1788582640568,"version":"build-2803163510"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Inherited renal diseases represent 20% of the causes of end-stage renal diseases. Fabry disease, an X-linked lysosomal storage disorder, results from \u03b1-galactosidase A deficient or absent activity followed by globotriaosylceramide (Gb3) accumulation and multiorgan involvement. In Fabry disease, kidney involvement starts early, during intrauterine life by the Gb3 deposition. Even if chronic kidney disease (CKD) is discovered later in adult life in Fabry disease patients, a decline in glomerular filtration rate (GFR) can occur during adolescence. The first clinical sign of kidney involvement is represented by albuminuria. So, early and close monitoring of kidneys function is required: albuminuria and proteinuria, urinary albumin-to-creatinine ratio, serum creatinine, or cystatin C to estimate GFR, while urinary sediment with phase-contrast microscopy under polarized light may be useful in those cases where leucocyte \u03b1-Gal A activity and <jats:italic>GLA<\/jats:italic> genotyping are not available. Children with Fabry disease and kidney involvement should receive enzyme replacement therapy and nephroprotective drugs (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) to prevent or slow the progressive loss of kidney functions. Early diagnosis of Fabry disease is important as enzyme replacement therapy reduces symptoms, improves clinical features and biochemical markers, and the quality of life. More importantly, early treatment could slow or stop progressive organ damage in later life.<\/jats:p>","DOI":"10.3389\/fped.2022.908657","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:43:31Z","timestamp":1654087411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Carmen","family":"Muntean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana Magdalena","family":"Starcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Stoica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Banescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and screening of patients with fabry disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther Clin Risk Manag."},{"key":"B2","first-page":"7","article-title":"Fet\u00e1ln\u00ed patologie Fabryho nemoci a mukopolysacharid\u00f3zy I [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]","volume":"34","author":"Elleder","year":"1998","journal-title":"Cesk Patol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J Inherit Metab Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15386\/mpr-2228","article-title":"Early clinical signs in lysosomal diseases","volume":"94","author":"Alkhzouz","year":"2021","journal-title":"Med Pharm Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00467-021-05076-x","article-title":"Fabry disease and kidney involvement: starting from childhood to understand the future","volume":"37","author":"Chimenz","year":"2022","journal-title":"Pediatr Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.12865\/CHSJ.45.03.04","article-title":"Demographic and clinical characteristics of the full 2015-2018 cohort of Romanian Fabry Disease patients","volume":"45","author":"Militaru","year":"2019","journal-title":"Curr Health Sci J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med."},{"key":"B9","unstructured":"Fabry Disease\n            BokhariSRA\n            ZulfiqarH\n            HarizA\n          Treasure Island (FL)StatPearls PublishingStatPearls2022"},{"key":"B10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40620-019-00663-6","article-title":"Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995-2019","volume":"33","author":"Capuano","year":"2020","journal-title":"J Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e7387","DOI":"10.1097\/MD.0000000000007387","article-title":"Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype","volume":"96","author":"Choi","year":"2017","journal-title":"Medicine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2012_130","article-title":"Newborn screening for lysosomal storage disorders in hungary","volume":"6","author":"Wittmann","year":"2012","journal-title":"JIMD Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","article-title":"Newborn screening for Fabry disease in the north-west of Spain","volume":"176","author":"Colon","year":"2017","journal-title":"Eur J Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur J Hum Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266\u2013X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"Fabry Pediatric Expert Panel. The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol Genet Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","article-title":"Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan","volume":"133","author":"Koto","year":"2021","journal-title":"Mol Genet Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J Hum Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1159\/000519095","article-title":"Next-generation sequencing-based genetic diagnostic strategies of inherited kidney diseases","author":"Zhang","year":"2021","journal-title":"Kidney Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant \u03b1-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"107","author":"Mitobe","year":"2012","journal-title":"Mol Genet Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF03402156","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes","volume":"8","author":"Germain","year":"2002","journal-title":"Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ymgmr.2018.10.004","article-title":"Fabry disease in a Japanese population-molecular and biochemical characteristics","volume":"17","author":"Sakuraba","year":"2018","journal-title":"Mol Genet Metab Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1502","DOI":"10.1002\/mgg3.1502","article-title":"Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening","volume":"8","author":"Sawada","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2169\/internalmedicine.0959-18","article-title":"Clinical diversity in patients with Anderson-Fabry disease with the R301Q mutation","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/diagnostics11101779","article-title":"High-Risk screening for Fabry disease: a nationwide study in Japan and Literature Review","volume":"11","author":"Sawada","year":"2021","journal-title":"Diagnostics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"103703","DOI":"10.1016\/j.ejmg.2019.103703","article-title":"Fabry disease caused by the GLA pPhe113Leu (pF113L) variant: Natural history in males","volume":"63","author":"Oliveira","year":"2020","journal-title":"Eur J Med Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.6515\/ACS.202107_37(4).20210601A","article-title":"2021 TSOC expert consensus on the clinical features, diagnosis, and clinical management of cardiac manifestations of Fabry Disease","volume":"37","author":"Hung","year":"2021","journal-title":"Acta Cardiol Sin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ymgme.2012.01.010","article-title":"Fabry disease: biochemical, pathological and structural studies of the \u03b1-galactosidase A with E66Q amino acid substitution","volume":"105","author":"Togawa","year":"2012","journal-title":"Mol Genet Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.gene.2015.09.088","article-title":"GLA variation pE66Q identified as the genetic etiology of Fabry disease using exome sequencing","volume":"575","author":"Peng","year":"2016","journal-title":"Gene."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/cge.13233","article-title":"pD313Y is more than just a polymorphism in Fabry disease","volume":"93","author":"du Moulin","year":"2018","journal-title":"Clin Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/cge.13237","article-title":"The D313Y genotype-pathogenic mutation or polymorphism?","volume":"93","author":"Oder","year":"2018","journal-title":"Clin Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A pArg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol Genet Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/8904_2018_146","article-title":"Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant","volume":"45","author":"Talbot","year":"2019","journal-title":"JIMD Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/8904_2012_167","article-title":"Questioning the Pathogenic Role of the GLA pAla143Thr \u201cMutation\u201d in Fabry Disease: Implications for Screening Studies and ERT","volume":"8","author":"Terryn","year":"2013","journal-title":"JIMD Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-Galactosidase A pA143T, a non-Fabry disease-causing variant Orphanet","volume":"11","author":"Lenders","year":"2016","journal-title":"J Rare Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2054358120985627","DOI":"10.1177\/2054358120985627","article-title":"Renal manifestations of Fabry disease: a narrative review","volume":"8","author":"Silva","year":"2021","journal-title":"Can J Kidney Health Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.12688\/f1000research.13708.1","article-title":"Variable phenotypic presentations of renal involvement in Fabry disease: a case series","volume":"7","author":"McCloskey","year":"2018","journal-title":"F1000Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.rceng.2017.09.001","article-title":"The pathophysiology of Fabry disease","volume":"218","author":"Olivera-Gonz\u00e1lez","year":"2018","journal-title":"Rev Clin Esp."},{"key":"B44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.20452\/pamw.15117","article-title":"Enzyme replacement therapy in Fabry disease in Poland: a position statement","volume":"130","author":"Nowicki","year":"2020","journal-title":"Pol Arch Intern Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol Genet Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e160002","DOI":"10.1177\/2326409816661351","article-title":"Small fiber neuropathy in Fabry disease: a review of pathophysiology and treatment","volume":"4","author":"Politei","year":"2016","journal-title":"J Inborn Errors Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2013a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin J Pain."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/jcm10081664","article-title":"Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up","volume":"10","author":"Carnicer-C\u00e1ceres","year":"2021","journal-title":"J Clin Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fcell.2020.00123","article-title":"Diverse Role of TGF-\u03b2 in Kidney Disease","volume":"8","author":"Gu","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2010.08.023","article-title":"Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease","volume":"102","author":"Chien","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules."},{"key":"B54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1002\/mgg3.1163","article-title":"Global research on Fabry's disease: demands for a rare disease","volume":"8","author":"Klingelh\u00f6fer","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics."},{"key":"B57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ndt\/gfx009","article-title":"Parapelvic cysts, a distinguishing feature of renal Fabry disease","volume":"33","author":"Pisani","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"B60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/j.pain.0000000000002152","article-title":"Fabry disease pain: patient and preclinical parallels","volume":"162","author":"Burand","year":"2021","journal-title":"Pain"},{"key":"B62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409816661353","article-title":"Dermatologic aspects of Fabry disease","volume":"4","author":"Luna","year":"2016","journal-title":"J Inborn Errors Metab Screen"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","article-title":"Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity","volume":"94","author":"Allen","year":"2010","journal-title":"Br J Ophthalmol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12886-016-0374-2","article-title":"Paediatric Fabry disease: prognostic significance of ocular changes for disease severity","volume":"16","author":"Kalkum","year":"2016","journal-title":"BMC Ophthalmol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10545-017-0051-5","article-title":"Hearing loss in children with Fabry disease","volume":"40","author":"Suntjens","year":"2017","journal-title":"J Inherit Metab Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review-how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.29245\/2572-9411\/2020\/2.1195","article-title":"Renal ultrasound contributes to Fabry Disease Diagnosis","volume":"5","author":"Azambuja Neves","year":"2020","journal-title":"J Rare Dis Res Treat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","article-title":"Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes","volume":"28","author":"GLAss","year":"2004","journal-title":"J Comput Assist Tomogr."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00467-017-3822-1","article-title":"Proteinuria in a male adolescent with hearing loss: questions","volume":"33","author":"Aksoy","year":"2018","journal-title":"Pediatr Nephrol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e112188","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS ONE."},{"key":"B73","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"B74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nefroe.2019.03.001","article-title":"Podocyturia in paediatric patients with Fabry disease","volume":"39","author":"Liern","year":"2019","journal-title":"Nefrologia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ndt\/gfab038","article-title":"Precision medicine in Fabry disease","volume":"36","author":"Lenders","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0168346","DOI":"10.1371\/journal.pone.0168346","article-title":"Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy","volume":"11","author":"Fall","year":"2016","journal-title":"PLoS ONE."},{"key":"B77","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia is significantly elevated in untreated vs treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J Nephrol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr."},{"key":"B80","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1186\/s13023-021-02136-1","article-title":"Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children's Hospital in China","volume":"16","author":"Shen","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ymgme.2013.07.005","article-title":"Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain","volume":"110","author":"Furujo","year":"2013","journal-title":"Mol Genet Metab."},{"key":"B83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"B84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2018.10.009","article-title":"Brain MRI findings in children and adolescents with Fabry disease","volume":"395","author":"Marchesoni","year":"2018","journal-title":"J Neurol Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2478\/rrlm-2019-0041","article-title":"Genetic testing in pediatrics-a narrative essay of challenges and possibilities in Romania","volume":"27","author":"Duicu","year":"2019","journal-title":"Rev Romana Med Lab."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6515613","DOI":"10.1155\/2018\/6515613","article-title":"Major organic involvement in women with Fabry disease in Argentina","volume":"2018","author":"Perretta","year":"2018","journal-title":"ScientificWorldJournal."},{"key":"B87","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol Genet Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/joim.12801","article-title":"Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease","volume":"284","author":"\u00dc\u00e7eyler","year":"2018","journal-title":"J Intern Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","article-title":"Hot topics in Fabry disease","volume":"94","author":"Cairns","year":"2018","journal-title":"Postgrad Med J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1590\/2175-8239-jbn-3910","article-title":"CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M)","volume":"40","author":"Pereira","year":"2018","journal-title":"J Bras Nefrol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.3390\/ijms21218080","article-title":"Biomarkers in Anderson-Fabry Disease","volume":"21","author":"Simonetta","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B93","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin Exp Nephrol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA Gene and LysoGb3: is it really Anderson-Fabry Disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J Med Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/genes11091091","article-title":"Biomarkers of Fabry nephropathy: review and future perspective","volume":"11","author":"Levstek","year":"2020","journal-title":"Genes."},{"key":"B98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease","volume":"141","author":"Riccio","year":"2019","journal-title":"Nephron."},{"key":"B99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000502907","article-title":"Early biomarkers of Fabry nephropathy: a review of the literature","volume":"143","author":"Riccio","year":"2019","journal-title":"Nephron."},{"key":"B100","doi-asserted-by":"publisher","first-page":"672","DOI":"10.21037\/cdt-20-981","article-title":"Fabry disease-what cardiologists can learn from the nephrologist: a narrative review","volume":"11","author":"Kurschat","year":"2021","journal-title":"Cardiovasc Diagn Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0272-6386(83)80047-X","article-title":"Early renal failure in Fabry's disease","volume":"2","author":"Sheth","year":"1983","journal-title":"Am J Kidney Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B105","first-page":"59","article-title":"Renal involvement in paediatric Fabry disease","volume":"33","author":"Sestito","year":"2019","journal-title":"J Biol Regul Homeost Agents"},{"key":"B106","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.08091109","article-title":"Assessment of renal pathology and dysfunction in children with Fabry disease","volume":"5","author":"Ramaswami","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000464312","article-title":"Disease progression modeling to evaluate the effects of enzyme replacement therapy on kidney function in adult patients with the classic phenotype of Fabry disease","volume":"42","author":"Nowak","year":"2017","journal-title":"Kidney Blood Press Res."},{"key":"B112","first-page":"437","article-title":"Cystatin C as a marker of early changes of renal function in Fabry nephropathy","volume":"20","author":"Feriozzi","year":"2007","journal-title":"J Nephrol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000500570","article-title":"Evaluation of Beta 2-Microglobulin, Cystatin C, and Lipocalin-2 as Renal Biomarkers for Patients with Fabry Disease","volume":"143","author":"Braga","year":"2019","journal-title":"Nephron."},{"key":"B114","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol Genet Metab."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics."},{"key":"B117","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol Genet Metab."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"B119","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1093\/ndt\/gfr084","article-title":"Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique","volume":"26","author":"Selvarajah","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B121","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5527\/wjn.v6.i5.221","article-title":"Podocyturia: Potential applications and current limitations","volume":"6","author":"Trimarchi","year":"2017","journal-title":"World J Nephrol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/ndt\/gfs074","article-title":"Mass spectrometry as a novel method for detection of podocyturia in pre-eclampsia","volume":"28","author":"Garovic","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1681\/ASN.2013020173","article-title":"Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases","volume":"24","author":"Wickman","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ckj\/sfy081","article-title":"Podocyturia: why it may have added value in rare diseases","volume":"12","author":"Sanchez-Ni\u00f1o","year":"2018","journal-title":"Clin Kidney J."},{"key":"B125","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta."},{"key":"B127","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fmed.2017.00073","article-title":"Rediscovering Beta-2 microglobulin as a biomarker across the spectrum of kidney diseases","volume":"4","author":"Argyropoulos","year":"2017","journal-title":"Front Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrneph.2017.101","article-title":"Uromodulin: from physiology to rare and complex kidney disorders","volume":"13","author":"Devuyst","year":"2017","journal-title":"Nat Rev Nephrol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e15808","DOI":"10.1097\/MD.0000000000015808","article-title":"Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients","volume":"98","author":"Steubl","year":"2019","journal-title":"Medicine."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol Biosyst."},{"key":"B131","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jmedgenet-2019-106030","article-title":"Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease","volume":"57","author":"Doykov","year":"2020","journal-title":"J Med Genet."},{"key":"B132","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s10545-008-0900-3","article-title":"Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy","volume":"31","author":"Vylet'al","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ki.2011.134","article-title":"The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease","volume":"80","author":"Rampoldi","year":"2011","journal-title":"Kidney Int."},{"key":"B134","doi-asserted-by":"publisher","first-page":"205948","DOI":"10.1155\/2013\/205948","article-title":"Urine bikunin as a marker of renal impairment in Fabry's disease","volume":"2013","author":"Lepedda","year":"2013","journal-title":"Biomed Res Int."},{"key":"B135","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"B136","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"van der Veen","year":"2020","journal-title":"J Inherit Metab Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e0182379","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS ONE."},{"key":"B139","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2019","journal-title":"Kidney Int Rep."},{"key":"B140","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jimd.12052","article-title":"Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease","volume":"42","author":"Hennermann","year":"2019","journal-title":"J Inherit Metab Dis."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/ijms23031887","article-title":"Chaperone therapy in Fabry disease","volume":"23","author":"Weidemann","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur J Hum Genet."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS ONE."},{"key":"B147","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun."},{"key":"B149","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","article-title":"Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing","volume":"134","author":"Domm","year":"2021","journal-title":"Mol Genet Metab."},{"key":"B150","doi-asserted-by":"publisher","first-page":"9075","DOI":"10.4081\/cardiogenetics.2020.9075","article-title":"Gene therapy in Anderson-Fabry disease","volume":"10","author":"Spiniello","year":"2020","journal-title":"State of the Art and Future Perspectives Cardiogenetics."},{"key":"B151","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0590-7","article-title":"Pain management strategies for neuropathic pain in Fabry disease\u2013a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.908657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:57:24Z","timestamp":1666169844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.908657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":153,"alternative-id":["10.3389\/fped.2022.908657"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.908657","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"908657"}}